Sol-Gel net loss narrows to $3.7 million on lower R&D spending
Sol-Gel Technologies (NASDAQ:SLGL) reported a narrowed net loss for the first quarter of 2026, driven by a sharp reduction in research and development expenses as the clinical-stage biotechnology firm solidified its financing footprint.










